Please ensure Javascript is enabled for purposes of website accessibility
Apellis Pharmaceuticals, Inc. Stock Quote

Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)

Price as of September 27, 2022, 4:00 p.m. ET

You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Apellis Pharmaceuticals, Inc. Returns vs. S&P

1 Year 5 Year 5 Year Annualized Since IPO
APLS +76.16% +340%
S&P -17.97% +45.79% +7.83% +41%

Apellis Pharmaceuticals, Inc. Company Info

Apellis Pharmaceuticals, Inc.

News & Analysis

Here's Why Apellis Pharmaceuticals Stock Jumped as Much as 40.7% Today
Maxx Chatsko  |  Jan 7, 2020

The company's lead drug candidate bested a competitor's therapy on a key endpoint in a phase 3 trial.

Apellis' Lead Drug Tops Alexion's Blockbuster Soliris in a Pivotal Late-Stage Study
Keith Speights  |  Jan 7, 2020

Pegcetacoplan is the first drug to beat Soliris in improving hemoglobin levels in PNH patients.

Here's Why Apellis Pharmaceuticals Fell Today
Cory Renauer  |  Dec 5, 2019

It looks like Apellis could have another competitor.

3 Companies to Watch At Kidney Week 2019
David Haen  |  Oct 18, 2019

Keeping up with the news from major medical meetings has become a requirement for healthcare investors.

Here's Why Apellis Pharmaceuticals Is Tumbling Today
Maxx Chatsko  |  Sep 12, 2019

The company is issuing convertible debt to pad its balance sheet and fund late-stage clinical trials.

3 Biotech Stocks That Could Double Your Money
Cory Renauer  |  Jul 14, 2019

Here's what you need to know about the upgrades and bullish price targets analysts recently slapped on these drugmakers.

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.


Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.